ZEUS System (Zio Watch) vs Eko Low Ejection Fraction Tool (ELEFT)

Tool B (ELEFT) offers a highly integrated and rapid screening experience, providing results in approximately 15 seconds during a routine physical exam, which minimizes disruption to existing clinical workflows. In contrast, Tool A (ZEUS System) involves a wearable device for continuous monitoring over several days, requiring greater patient adherence and a longer engagement period, despite offering patient and provider apps for management.

Tool A (ZEUS System) provides comprehensive, long-term continuous monitoring for up to 14 days, detecting and characterizing AFib and other cardiac arrhythmias with high physician agreement (99%) and offering detailed AFib burden estimates. While Tool B (ELEFT) offers valuable early screening for low ejection fraction, Tool A's in-depth diagnostic and characterization capabilities for complex, intermittent arrhythmias provide a more complete clinical picture for treatment decisions.

While both tools require contacting the vendor for specific pricing, Tool B (as part of Eko's SENSORA platform) has a clear and finalized CMS reimbursement rate of $128.90 per use, which significantly enhances its value proposition and financial viability for healthcare providers. Tool A's pricing remains opaque, and while a related iRhythm product had a proposed CMS rate, it is not as definitive for the ZEUS system itself.

Tool B is explicitly positioned as part of the 'SENSORAu2122 Cardiac Early Detection Platform,' an 'enterprise solution,' with extensive support documentation and guides tailored for various enterprise roles, including institution, program, clinician, and IT administrators. While Tool A is cloud-based and offers provider tools, Tool B demonstrates a more comprehensive and structured approach to enterprise-level deployment and management.

Tool A (ZEUS System) represents a significant innovation in continuous cardiac diagnostics through its AI-powered wearable biosensor, which collects both ECG and PPG data for long-term, comprehensive detection and characterization of AFib burden. While Tool B's point-of-care AI for rapid heart failure screening is highly impactful, Tool A's multi-modal data collection and continuous monitoring for detailed arrhythmia diagnosis demonstrate a broader scope of technological advancement.

Tool B, as part of the SENSORAu2122 platform, offers a comprehensive and clearly structured support ecosystem for enterprise clients, including dedicated help centers, detailed guides for various user roles (e.g., IT, admin, clinicians), and transparent support contact channels with defined response times. Tool A mentions patient and provider apps with educational content and 24/7 customer support, but the breadth of documented enterprise-specific resources appears more extensive for Tool B.